Stereotaxis Niobe(R) System Receives Highest Reimbursement Classification in Japan

Stereotaxis Niobe(R) System Receives Highest Reimbursement Classification in
Japan

ST. LOUIS, Oct. 23, 2013 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS)
announced today that the Ministry of Health, Labor and Welfare (MHLW) in Japan
has classified its Niobe® Magnetic Navigation System as a C2 medical device.
The C2 classification recognizes the Niobe system as a new, distinctive
technology with clinical benefits and is the highest of five reimbursement
categories for medical devices in Japan. The MHLW also approved reimbursement
for two electrophysiology (EP) ablation catheters compatible with Niobe
magnetic navigation, effective October 1, 2013.

Japan's MHLW, which controls the country's reimbursement rates, will establish
a more permanent "technical fee" for procedures using the Niobe system during
its biennial review of insurance reimbursement pricing for C2 devices before
April 1, 2014. Until then and effective October 1, 2013, MHLW authorized a
temporary "technical fee" of 343,700 yen (or approximately $3,500) per Niobe
procedure, which the Company says sufficiently covers the costs associated
with Niobe's disposable unit for catheter advancement (QuikCAS).

This milestone represents an important step toward a more permanent
reimbursement coverage of the Niobe system in Japan, the second largest
medical device market worldwide, behind the U.S. Stereotaxis received Shonin,
or regulatory, approval of Niobe in Japan in March and is in the process of
selecting an in-country distributor, identifying potential customers and
recruiting for part-time resources.

About Stereotaxis

Stereotaxis is a healthcare technology and innovation leader in the
development of robotic cardiology instrument navigation systems designed to
enhance the treatment of arrhythmias and coronary disease, as well as
information management solutions for the interventional lab. With over 100
patents for use in a hospital's interventional surgical suite, Stereotaxis
helps physicians around the world provide unsurpassed patient care with
robotic precision and safety, improved lab efficiency and productivity, and
enhanced collaboration of life-saving information. Stereotaxis' core Epoch™
Solution includes the Niobe^® ES Remote Magnetic Navigation system, the
Odyssey^® portfolio of lab optimization, networking and patient information
management systems and the Vdrive^™ Robotic Mechanical Navigation system and
consumables.

The core components of Stereotaxis systems have received regulatory clearance
in the U.S., Europe, Canada and elsewhere. The V-Sono^™ ICE catheter
manipulator has received U.S. clearance, and the V-Loop™ circular catheter
manipulator is currently in clinical trials in order to obtain clearance by
the U.S. Food and Drug Administration. For more information, please visit
www.stereotaxis.com

This press release includes statements that may constitute "forward-looking"
statements, usually containing the words "believe," "estimate," "project,"
"expect" or similar expressions. Forward-looking statements inherently involve
risks and uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or contribute to
such differences include, but are not limited to, the Company's ability to
raise additional capital or otherwise address ongoing liquidity challenges on
a timely basis and on terms that are acceptable, its ability to continue to
manage expenses and cash burn rate at sustainable levels, its ability to
continue to work with lenders to extend, repay or refinance indebtedness on
acceptable terms or at all, continued acceptance of the Company's products in
the marketplace, the effect of global economic conditions on the ability and
willingness of customers to purchase its systems and the timing of such
purchases, the outcome of various shareholder litigation filed against
Stereotaxis, competitive factors, changes resulting from the recently enacted
healthcare reform in the U.S., including changes in government reimbursement
procedures, dependence upon third-party vendors, timing of regulatory
approvals, and other risks discussed in the Company's periodic and other
filings with the Securities and Exchange Commission. By making these
forward-looking statements, the Company undertakes no obligation to update
these statements for revisions or changes after the date of this release.
There can be no assurance that the Company will recognize revenue related to
its purchase orders and other commitments in any particular period or at all
because some of these purchase orders and other commitments are subject to
contingencies that are outside of the Company's control. In addition, these
orders and commitments may be revised, modified, delayed or canceled, either
by their express terms, as a result of negotiations, or by overall project
changes or delays.

CONTACT: Press Contact:
         Frank Cheng
         Senior Vice President, Marketing and
         Business Development
         314-678-6111
        
         Investor Contact:
         Todd Kehrli / Jim Byers
         MKR Group, Inc.
         323-468-2300
         stxs@mkr-group.com
 
Press spacebar to pause and continue. Press esc to stop.